APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Drug Safety and Pharmacovigilance (PV) Software

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Drug Safety and Pharmacovigilance (PV) Software Market Outlook and Growth Opportunities 2026

Report ID 174123180415 April 2026Not stated

Choose your research edition.

Industry ResearchDrug Safety and Pharmacovigilance (PV) Software Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Drug Safety and Pharmacovigilance (PV) Software Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Drug Safety and Pharmacovigilance (PV) Software Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drug Safety and Pharmacovigilance (PV) Software Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Drug Safety and Pharmacovigilance (PV) Software Market Analysis and Forecast 2026-2032250 pages · $4,950 USD

Market perspective

The global Drug Safety and Pharmacovigilance (PV) Software market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Drug Safety and Pharmacovigilance (PV) Software is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drug Safety and Pharmacovigilance (PV) Software is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drug Safety and Pharmacovigilance (PV) Software is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Drug Safety and Pharmacovigilance (PV) Software market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Drug Safety and Pharmacovigilance (PV) Software market include Oracle, Veeva Systems, ArisGlobal, IQVIA, EXTEDO, RxLogix, Ennov, Uppsala Monitoring Centre and Medidata, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Drug Safety and Pharmacovigilance (PV) Software market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drug Safety and Pharmacovigilance (PV) Software and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drug Safety and Pharmacovigilance (PV) Software revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Drug Safety and Pharmacovigilance (PV) Software market.

Drug Safety and Pharmacovigilance (PV) Software Segment by Company

Oracle

Veeva Systems

ArisGlobal

IQVIA

EXTEDO

RxLogix

Ennov

Uppsala Monitoring Centre

Medidata

Clarivate

AB Cube

Cloudbyz

Cognizant Technology

Taimei Technology

eMedyun

Bioknow

Singedi Health

Drug Safety and Pharmacovigilance (PV) Software Segment by Type

On-Premises

Cloud-Based

Drug Safety and Pharmacovigilance (PV) Software Segment by Application

Pharma and Biotech Companies

Contract Research Organizations (CROs)

Business Process Outsourcing (BPO) Firms

Other

Drug Safety and Pharmacovigilance (PV) Software Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drug Safety and Pharmacovigilance (PV) Software status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Drug Safety and Pharmacovigilance (PV) Software key companies, revenue, market share, and recent developments.

3. To split the Drug Safety and Pharmacovigilance (PV) Software breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Drug Safety and Pharmacovigilance (PV) Software market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drug Safety and Pharmacovigilance (PV) Software significant trends, drivers, influence factors in global and regions.

6. To analyze Drug Safety and Pharmacovigilance (PV) Software competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug Safety and Pharmacovigilance (PV) Software market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drug Safety and Pharmacovigilance (PV) Software and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug Safety and Pharmacovigilance (PV) Software.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drug Safety and Pharmacovigilance (PV) Software industry.

Chapter 3: Detailed analysis of Drug Safety and Pharmacovigilance (PV) Software company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Drug Safety and Pharmacovigilance (PV) Software in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Drug Safety and Pharmacovigilance (PV) Software in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drug Safety and Pharmacovigilance (PV) Software Industry Trends Table 2. Drug Safety and Pharmacovigilance (PV) Software Industry Drivers Table 3. Drug Safety and Pharmacovigilance (PV) Software Industry Opportunities and Challenges Table 4. Drug Safety and Pharmacovigilance (PV) Software Industry Restraints Table 5. Global Drug Safety and Pharmacovigilance (PV) Software Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Company (2021-2026) Table 7. Global Drug Safety and Pharmacovigilance (PV) Software Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Drug Safety and Pharmacovigilance (PV) Software Key Company Manufacturing Base & Headquarters Table 9. Global Drug Safety and Pharmacovigilance (PV) Software Company, Product Type & Application Table 10. Global Drug Safety and Pharmacovigilance (PV) Software Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Drug Safety and Pharmacovigilance (PV) Software by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of On-Premises Table 15. Significant Companies of Cloud-Based Table 16. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type (2021-2026) Table 20. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Pharma and Biotech Companies Table 22. Significant Companies of Contract Research Organizations (CROs) Table 23. Significant Companies of Business Process Outsourcing (BPO) Firms Table 24. Significant Companies of Other Table 25. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application (2021-2026) Table 29. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application (2027-2032) Table 30. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Region (2021-2026) Table 33. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Region (2027-2032) Table 35. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value Market Share by Country (2021-2026) Table 38. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value Market Share by Country (2027-2032) Table 40. Oracle Company Information Table 41. Oracle Business Overview Table 42. Oracle Drug Safety and Pharmacovigilance (PV) Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Oracle Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 44. Oracle Recent Development Table 45. Veeva Systems Company Information Table 46. Veeva Systems Business Overview Table 47. Veeva Systems Drug Safety and Pharmacovigilance (PV) Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Veeva Systems Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 49. Veeva Systems Recent Development Table 50. ArisGlobal Company Information Table 51. ArisGlobal Business Overview Table 52. ArisGlobal Drug Safety and Pharmacovigilance (PV) Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. ArisGlobal Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 54. ArisGlobal Recent Development Table 55. IQVIA Company Information Table 56. IQVIA Business Overview Table 57. IQVIA Drug Safety and Pharmacovigilance (PV) Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. IQVIA Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 59. IQVIA Recent Development Table 60. EXTEDO Company Information Table 61. EXTEDO Business Overview Table 62. EXTEDO Drug Safety and Pharmacovigilance (PV) Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. EXTEDO Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 64. EXTEDO Recent Development Table 65. RxLogix Company Information Table 66. RxLogix Business Overview Table 67. RxLogix Drug Safety and Pharmacovigilance (PV) Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. RxLogix Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 69. RxLogix Recent Development Table 70. Ennov Company Information Table 71. Ennov Business Overview Table 72. Ennov Drug Safety and Pharmacovigilance (PV) Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Ennov Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 74. Ennov Recent Development Table 75. Uppsala Monitoring Centre Company Information Table 76. Uppsala Monitoring Centre Business Overview Table 77. Uppsala Monitoring Centre Drug Safety and Pharmacovigilance (PV) Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Uppsala Monitoring Centre Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 79. Uppsala Monitoring Centre Recent Development Table 80. Medidata Company Information Table 81. Medidata Business Overview Table 82. Medidata Drug Safety and Pharmacovigilance (PV) Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Medidata Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 84. Medidata Recent Development Table 85. Clarivate Company Information Table 86. Clarivate Business Overview Table 87. Clarivate Drug Safety and Pharmacovigilance (PV) Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Clarivate Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 89. Clarivate Recent Development Table 90. AB Cube Company Information Table 91. AB Cube Business Overview Table 92. AB Cube Drug Safety and Pharmacovigilance (PV) Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. AB Cube Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 94. AB Cube Recent Development Table 95. Cloudbyz Company Information Table 96. Cloudbyz Business Overview Table 97. Cloudbyz Drug Safety and Pharmacovigilance (PV) Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Cloudbyz Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 99. Cloudbyz Recent Development Table 100. Cognizant Technology Company Information Table 101. Cognizant Technology Business Overview Table 102. Cognizant Technology Drug Safety and Pharmacovigilance (PV) Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Cognizant Technology Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 104. Cognizant Technology Recent Development Table 105. Taimei Technology Company Information Table 106. Taimei Technology Business Overview Table 107. Taimei Technology Drug Safety and Pharmacovigilance (PV) Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. Taimei Technology Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 109. Taimei Technology Recent Development Table 110. eMedyun Company Information Table 111. eMedyun Business Overview Table 112. eMedyun Drug Safety and Pharmacovigilance (PV) Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. eMedyun Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 114. eMedyun Recent Development Table 115. Bioknow Company Information Table 116. Bioknow Business Overview Table 117. Bioknow Drug Safety and Pharmacovigilance (PV) Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 118. Bioknow Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 119. Bioknow Recent Development Table 120. Singedi Health Company Information Table 121. Singedi Health Business Overview Table 122. Singedi Health Drug Safety and Pharmacovigilance (PV) Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 123. Singedi Health Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 124. Singedi Health Recent Development Table 125. Research Programs/Design for This Report Table 126. Authors List of This Report Table 127. Secondary Sources Table 128. Primary Sources List of Figures Figure 1. Drug Safety and Pharmacovigilance (PV) Software Product Image Figure 2. Global Drug Safety and Pharmacovigilance (PV) Software Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drug Safety and Pharmacovigilance (PV) Software Market Size (2021-2032) & (US$ Million) Figure 4. Global Drug Safety and Pharmacovigilance (PV) Software Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. On-Premises Image Figure 8. Cloud-Based Image Figure 9. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type (2021-2032) Figure 12. Pharma and Biotech Companies Image Figure 13. Contract Research Organizations (CROs) Image Figure 14. Business Process Outsourcing (BPO) Firms Image Figure 15. Other Image Figure 16. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application (2021-2032) Figure 19. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Drug Safety and Pharmacovigilance (PV) Software Sales Value (2021-2032) & (US$ Million) Figure 22. North America Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Drug Safety and Pharmacovigilance (PV) Software Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Drug Safety and Pharmacovigilance (PV) Software Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Drug Safety and Pharmacovigilance (PV) Software Sales Value (2021-2032) & (US$ Million) Figure 28. South America Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Drug Safety and Pharmacovigilance (PV) Software Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • On-Premises
  • Cloud-Based
Applications
  • Pharma and Biotech Companies
  • Contract Research Organizations (CROs)
  • Business Process Outsourcing (BPO) Firms
  • Other
Companies covered
  • Oracle
  • Veeva Systems
  • ArisGlobal
  • IQVIA
  • EXTEDO
  • RxLogix
  • Ennov
  • Uppsala Monitoring Centre
  • Medidata
  • Clarivate
  • AB Cube
  • Cloudbyz
  • Cognizant Technology
  • Taimei Technology
  • eMedyun
  • Bioknow
  • Singedi Health

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drug Safety and Pharmacovigilance (PV) Software Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drug Safety and Pharmacovigilance (PV) Software Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Drug Safety and Pharmacovigilance (PV) Software Market Dynamics
  1. 2.1 Drug Safety and Pharmacovigilance (PV) Software Industry Trends
  2. 2.2 Drug Safety and Pharmacovigilance (PV) Software Industry Drivers
  3. 2.3 Drug Safety and Pharmacovigilance (PV) Software Industry Opportunities and Challenges
  4. 2.4 Drug Safety and Pharmacovigilance (PV) Software Industry Restraints
3 Drug Safety and Pharmacovigilance (PV) Software Market by Company
  1. 3.1 Global Drug Safety and Pharmacovigilance (PV) Software Company Revenue Ranking in 2025
  2. 3.2 Global Drug Safety and Pharmacovigilance (PV) Software Revenue by Company (2021-2026)
  3. 3.3 Global Drug Safety and Pharmacovigilance (PV) Software Company Ranking (2024-2026)
  4. 3.4 Global Drug Safety and Pharmacovigilance (PV) Software Company Manufacturing Base and Headquarters
  5. 3.5 Global Drug Safety and Pharmacovigilance (PV) Software Company Product Type and Application
  6. 3.6 Global Drug Safety and Pharmacovigilance (PV) Software Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Drug Safety and Pharmacovigilance (PV) Software Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Drug Safety and Pharmacovigilance (PV) Software Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Drug Safety and Pharmacovigilance (PV) Software Market by Type
  1. 4.1 Drug Safety and Pharmacovigilance (PV) Software Type Introduction
  2. 4.1.1 On-Premises
  3. 4.1.2 Cloud-Based
  4. 4.2 Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Type
  5. 4.2.1 Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Type (2021-2032)
  7. 4.2.3 Global Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type (2021-2032)
5 Drug Safety and Pharmacovigilance (PV) Software Market by Application
  1. 5.1 Drug Safety and Pharmacovigilance (PV) Software Application Introduction
  2. 5.1.1 Pharma and Biotech Companies
  3. 5.1.2 Contract Research Organizations (CROs)
  4. 5.1.3 Business Process Outsourcing (BPO) Firms
  5. 5.1.4 Other
  6. 5.2 Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Application
  7. 5.2.1 Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Application (2021-2032)
  9. 5.2.3 Global Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application (2021-2032)
6 Drug Safety and Pharmacovigilance (PV) Software Regional Value Analysis
  1. 6.1 Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Region (2021-2032)
  3. 6.2.1 Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Region: 2021-2026
  4. 6.2.2 Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drug Safety and Pharmacovigilance (PV) Software Sales Value (2021-2032)
  7. 6.3.2 North America Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Drug Safety and Pharmacovigilance (PV) Software Sales Value (2021-2032)
  10. 6.4.2 Europe Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Drug Safety and Pharmacovigilance (PV) Software Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Drug Safety and Pharmacovigilance (PV) Software Sales Value (2021-2032)
  16. 6.6.2 South America Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Drug Safety and Pharmacovigilance (PV) Software Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Country, 2025 VS 2032
7 Drug Safety and Pharmacovigilance (PV) Software Country-level Value Analysis
  1. 7.1 Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Country (2021-2032)
  3. 7.2.1 Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Country (2021-2026)
  4. 7.2.2 Global Drug Safety and Pharmacovigilance (PV) Software Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Drug Safety and Pharmacovigilance (PV) Software Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Drug Safety and Pharmacovigilance (PV) Software Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Oracle
  2. 8.1.1 Oracle Company Information
  3. 8.1.2 Oracle Business Overview
  4. 8.1.3 Oracle Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Oracle Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  6. 8.1.5 Oracle Recent Developments
  7. 8.2 Veeva Systems
  8. 8.2.1 Veeva Systems Company Information
  9. 8.2.2 Veeva Systems Business Overview
  10. 8.2.3 Veeva Systems Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Veeva Systems Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  12. 8.2.5 Veeva Systems Recent Developments
  13. 8.3 ArisGlobal
  14. 8.3.1 ArisGlobal Company Information
  15. 8.3.2 ArisGlobal Business Overview
  16. 8.3.3 ArisGlobal Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  17. 8.3.4 ArisGlobal Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  18. 8.3.5 ArisGlobal Recent Developments
  19. 8.4 IQVIA
  20. 8.4.1 IQVIA Company Information
  21. 8.4.2 IQVIA Business Overview
  22. 8.4.3 IQVIA Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  23. 8.4.4 IQVIA Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  24. 8.4.5 IQVIA Recent Developments
  25. 8.5 EXTEDO
  26. 8.5.1 EXTEDO Company Information
  27. 8.5.2 EXTEDO Business Overview
  28. 8.5.3 EXTEDO Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  29. 8.5.4 EXTEDO Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  30. 8.5.5 EXTEDO Recent Developments
  31. 8.6 RxLogix
  32. 8.6.1 RxLogix Company Information
  33. 8.6.2 RxLogix Business Overview
  34. 8.6.3 RxLogix Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  35. 8.6.4 RxLogix Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  36. 8.6.5 RxLogix Recent Developments
  37. 8.7 Ennov
  38. 8.7.1 Ennov Company Information
  39. 8.7.2 Ennov Business Overview
  40. 8.7.3 Ennov Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Ennov Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  42. 8.7.5 Ennov Recent Developments
  43. 8.8 Uppsala Monitoring Centre
  44. 8.8.1 Uppsala Monitoring Centre Company Information
  45. 8.8.2 Uppsala Monitoring Centre Business Overview
  46. 8.8.3 Uppsala Monitoring Centre Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Uppsala Monitoring Centre Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  48. 8.8.5 Uppsala Monitoring Centre Recent Developments
  49. 8.9 Medidata
  50. 8.9.1 Medidata Company Information
  51. 8.9.2 Medidata Business Overview
  52. 8.9.3 Medidata Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Medidata Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  54. 8.9.5 Medidata Recent Developments
  55. 8.10 Clarivate
  56. 8.10.1 Clarivate Company Information
  57. 8.10.2 Clarivate Business Overview
  58. 8.10.3 Clarivate Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Clarivate Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  60. 8.10.5 Clarivate Recent Developments
  61. 8.11 AB Cube
  62. 8.11.1 AB Cube Company Information
  63. 8.11.2 AB Cube Business Overview
  64. 8.11.3 AB Cube Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  65. 8.11.4 AB Cube Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  66. 8.11.5 AB Cube Recent Developments
  67. 8.12 Cloudbyz
  68. 8.12.1 Cloudbyz Company Information
  69. 8.12.2 Cloudbyz Business Overview
  70. 8.12.3 Cloudbyz Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Cloudbyz Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  72. 8.12.5 Cloudbyz Recent Developments
  73. 8.13 Cognizant Technology
  74. 8.13.1 Cognizant Technology Company Information
  75. 8.13.2 Cognizant Technology Business Overview
  76. 8.13.3 Cognizant Technology Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Cognizant Technology Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  78. 8.13.5 Cognizant Technology Recent Developments
  79. 8.14 Taimei Technology
  80. 8.14.1 Taimei Technology Company Information
  81. 8.14.2 Taimei Technology Business Overview
  82. 8.14.3 Taimei Technology Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Taimei Technology Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  84. 8.14.5 Taimei Technology Recent Developments
  85. 8.15 eMedyun
  86. 8.15.1 eMedyun Company Information
  87. 8.15.2 eMedyun Business Overview
  88. 8.15.3 eMedyun Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  89. 8.15.4 eMedyun Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  90. 8.15.5 eMedyun Recent Developments
  91. 8.16 Bioknow
  92. 8.16.1 Bioknow Company Information
  93. 8.16.2 Bioknow Business Overview
  94. 8.16.3 Bioknow Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Bioknow Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  96. 8.16.5 Bioknow Recent Developments
  97. 8.17 Singedi Health
  98. 8.17.1 Singedi Health Company Information
  99. 8.17.2 Singedi Health Business Overview
  100. 8.17.3 Singedi Health Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Singedi Health Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  102. 8.17.5 Singedi Health Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst